ADC Therapeutics SA Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset
ADC Therapeutics SA (ADCT) reported Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset of -$3.44 million for the 12-month period ending 2022-12-31, per its 20-F filed 2023-03-15.
Discontinued › Income Statement › Other Income
ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset · last filed 2023-03-15
| Period end | Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset 12 month | Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset 12 month as first filed |
|---|---|---|
| 2022-12-31 | -$3.44M 20-F · filed 2023-03-15 | |
| 2021-12-31 | $310.00K 20-F · filed 2023-03-15 | -$310.00K 20-F · filed 2022-03-17 |
| 2019-12-31 | -$686.00K 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |